Next Article in Journal
Variable Frequencies of Apolipoprotein E Genotypes and Its Effect on Serum Lipids in the Guangxi Zhuang and Han Children
Previous Article in Journal
New User-Friendly Approach to Obtain an Eisenberg Plot and Its Use as a Practical Tool in Protein Sequence Analysis
Review

Epigallocatechin-3-gallate (EGCG) for Clinical Trials: More Pitfalls than Promises?

1
Department of Cardiology, Angiology and Pneumology, University of Heidelberg, D-69120 Heidelberg, Germany
2
Faculty of Medicine, University of Heidelberg, D-69120, Heidelberg, Germany
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2011, 12(9), 5592-5603; https://doi.org/10.3390/ijms12095592
Received: 14 July 2011 / Revised: 17 August 2011 / Accepted: 19 August 2011 / Published: 31 August 2011
(This article belongs to the Section Biochemistry)
Epigallocatechin-3-gallate (EGCG), the main and most significant polyphenol in green tea, has shown numerous health promoting effects acting through different pathways, as antioxidant, anti-inflammatory and anti-atherogenic agent, showing gene expression activity, functioning through growth factor-mediated pathways, the mitogen-activated protein kinase-dependent pathway, the ubiquitin/proteasome degradation pathway, as well as eliciting an amyloid protein remodeling activity. However, epidemiological inferences are sometimes conflicting and in vitro and in vivo studies may seem discrepant. Current knowledge on how to enhance bioavailability could be the answer to some of these issues. Furthermore, dose levels, administration frequency and potential side effects remain to be examined. View Full-Text
Keywords: epigallocatechin-3-gallate; green tea; bioavailability epigallocatechin-3-gallate; green tea; bioavailability
Show Figures

Graphical abstract

MDPI and ACS Style

Mereles, D.; Hunstein, W. Epigallocatechin-3-gallate (EGCG) for Clinical Trials: More Pitfalls than Promises? Int. J. Mol. Sci. 2011, 12, 5592-5603. https://doi.org/10.3390/ijms12095592

AMA Style

Mereles D, Hunstein W. Epigallocatechin-3-gallate (EGCG) for Clinical Trials: More Pitfalls than Promises? International Journal of Molecular Sciences. 2011; 12(9):5592-5603. https://doi.org/10.3390/ijms12095592

Chicago/Turabian Style

Mereles, Derliz, and Werner Hunstein. 2011. "Epigallocatechin-3-gallate (EGCG) for Clinical Trials: More Pitfalls than Promises?" International Journal of Molecular Sciences 12, no. 9: 5592-5603. https://doi.org/10.3390/ijms12095592

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop